Form 8-K - Current report:
SEC Accession No. 0001213900-16-012164
Filing Date
2016-03-31
Accepted
2016-03-31 17:05:14
Documents
4
Period of Report
2016-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k032816_immucellcorp.htm 8-K 32594
2 CONSTRUCTION LOAN NOTE FOR $2,000,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR f8k032816ex99i_immucell.htm EX-99.1 53431
3 TERM LOAN NOTE FOR $2,500,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF TD BA f8k032816ex99ii_immucell.htm EX-99.2 62013
4 SECOND AMENDED AND RESTATED LOAN AGREEMENT (COVENANTS) BETWEEN IMMUCELL CORPORAT f8k032816ex99iii_immucell.htm EX-99.3 30888
  Complete submission text file 0001213900-16-012164.txt   180146
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 161543959
SIC: 2835 In Vitro & In Vivo Diagnostic Substances